Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 202 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Influenza Type A Clear all

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxovirdae, H5N1 Virus
Interventions: VRC-AVIDNA036-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Not listed
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Tucson, Arizona • Chapel Hill, North Carolina • Columbus, Ohio

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™ COVID-19/Flu A&B Panel; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: 2 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Pelham, Alabama • Brooklyn, New York

Conditions: Influenza
Interventions: A/Arkansas/08/2020 (pH1N1), Sham/Diluent (1X SPG+Arg+Gel); Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 4
States / cities: Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more

Conditions: Influenza
Interventions: Influenza A/H7N7 Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: MF59-eH1N1_f; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 654 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 28
States / cities: Bentonville, Arkansas • Fort Smith, Arkansas • Canoga Park, California + 25 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: Aqueous Cream B.P., Imiquimod, Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID); Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: SARS-CoV-2 Infection, Influenza A, Influenza B
Interventions: Aptitude Medical Systems Metrix COVID/Flu Test; Diagnostic Test
Lead sponsor: Aptitude Medical Systems; Industry
Eligibility: 2 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Trussville, Alabama • Goleta, California • Chelmsford, Massachusetts

Conditions: Immune Response to Influenza Vaccine, Influenza A Virus Infection, Influenza B Virus Infection
Interventions: LAIV, IIV; Biological
Lead sponsor: Marshfield Clinic Research Foundation; Other
Eligibility: 5 Years to 17 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Marshfield, Wisconsin

Conditions: Influenza -Like Illness, Influenza A, Influenza Type B, Respiratory Viral Infection, Respiratory Tract Infections
Interventions: Not listed
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years and older
Enrollment: 5,233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Mateo, California

Conditions: SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
Interventions: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel; Diagnostic Test
Lead sponsor: Thermo Fisher Scientific, Inc; Industry
Eligibility: Not listed
Enrollment: 1,909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 17
States / cities: San Diego, California • Lake City, Florida • Miami, Florida + 13 more

Conditions: Influenza
Interventions: ASO3 Adjuvant, Influenza A/H5N1 Vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Avian Influenza
Interventions: AS03, MF59, Monovalent Influenza A/H5N8 vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Iowa City, Iowa • Cincinnati, Ohio • Seattle, Washington

Conditions: Influenza, Human
Interventions: Flu Symptoms; Device
Lead sponsor: Sekisui Diagnostics, LLC; Industry
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 14
States / cities: Little Rock, Arkansas • Coral Gables, Florida • Lauderdale Lakes, Florida + 11 more

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: Baltimore, Maryland • St Louis, Missouri • Durham, North Carolina + 3 more

Conditions: Influenza, Human
Interventions: Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3., Flu Pandemic mRNA_ Dose level 4, Flu Pandemic mRNA_Dose level 5, Flu Pandemic mRNA_Dose level 6, Influenza virus vaccine, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 991 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Anniston, Alabama • Little Rock, Arkansas • Fort Collins, Colorado + 18 more

Conditions: Influenza
Interventions: Monovalent influenza A/H7N9 virus vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Seasonal Influenza DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Stanford, California • Iowa City, Iowa • St Louis, Missouri + 1 more

Conditions: Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
Interventions: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 60 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

Collection and Extraction of Respiratory Specimens

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use

pH1N1 Blinded Challenge Study

H5 Adult - Chiron Study of Bird Flu Vaccine

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months

H5N1 With or Without Topical Aldara in Healthy Adults

Higher Dose Intradermal H5 Vaccine

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

Home Testing of Respiratory Illness

Project STARFISH - PRJ0002679

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

Assessment of the Clinical Performance of the ARROW-FLU System

Novartis H1N1 Vaccine in Pregnant Women

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

H7N9 Boost in Healthy Adults

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies